article Open AccessTop 1% cited

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

JNCI Journal of the National Cancer Institute · 2005 · Vol. 97(17) · pp. 1262–1271

Paul E. Goss✉(Harvard University Press)James N. Ingle(Mayo Clinic)Silvana Martino(Cancer Institute (WIA))Nicholas J. Robert(Inova Fairfax Hospital)Hyman B. Muss(University of Vermont)Martine Piccart(Université Libre de Bruxelles)Monica Castiglione(International Breast Cancer Study Group)Dongsheng Tu(Ontario Institute for Cancer Research)Lois E. Shepherd(Ontario Institute for Cancer Research)Kathleen I. Pritchard(University of Toronto)Robert B. Livingston(University of Washington)Nancy E. Davidson(Johns Hopkins University)Larry Norton(Memorial Sloan Kettering Cancer Center)Edith A. Perez(WinnMed)Jeffrey S. Abrams(National Institutes of Health)David Cameron(Western General Hospital)Michael Palmer(Ontario Institute for Cancer Research)Joseph L. Pater(Ontario Institute for Cancer Research)

View via DOI Full-text PDF

Abstract

Letrozole after tamoxifen is well-tolerated and improves both disease-free and distant disease-free survival but not overall survival, except in node-positive patients.

Estrogen and related hormone effects Breast Cancer Treatment Studies Advanced Breast Cancer TherapiesLetrozoleMedicineHazard ratioBreast cancerTamoxifenInternal medicineInterim analysisAdjuvant therapyOncologyAromatase inhibitor

MeSH terms

LetrozoleAgedAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, PhytogenicBreast NeoplasmsFemaleHumansLymphatic MetastasisMiddle AgedNitrilesReceptors, EstrogenReceptors, ProgesteroneTamoxifenTriazolesIncidence

Citations

1,117

FWCI

72.87

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Effects of Age on the Detection and Management of Breast Cancer